MOZAVAPTAN

Details

Stereochemistry	RACEMIC
Molecular Formula	C27H29N3O2
Molecular Weight	427.5381
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN(C)C1CCCN(C(=O)C2=CC=C(NC(=O)C3=C(C)C=CC=C3)C=C2)C4=C1C=CC=C4

InChI

InChIKey=WRNXUQJJCIZICJ-UHFFFAOYSA-N

InChI=1S/C27H29N3O2/c1-19-9-4-5-10-22(19)26(31)28-21-16-14-20(15-17-21)27(32)30-18-8-13-24(29(2)3)23-11-6-7-12-25(23)30/h4-7,9-12,14-17,24H,8,13,18H2,1-3H3,(H,28,31)

HIDE SMILES / InChI

Molecular Formula	C27H29N3O2
Molecular Weight	427.5381
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: http://www.pharmacodia.com/yaodu/html/v1/chemicals/818f4654ed39a1c147d1e51a00ffb4cb.html
Curator's Comment: Description was created based on several sources, including http://adisinsight.springer.com/drugs/800001739 http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=33180

Mozavaptan hydrochloride was approved by Pharmaceuticals and Medical Devices Agency of Japan (PMDA) on July 26, 2006. It was developed and marketed as Physuline® by Otsuka in Japan. Mozavaptan hydrochloride is a vasopressin receptor antagonist. It is indicated for the treatment of hyponatremia due to excessive fluid retention when restriction of fluid intake is ineffective. Physuline® is available as film-coated tablet for oral use, containing 30 mg of Mozavaptan hydrochloride. The recommended dose is one tablet (30 mg) once daily after a meal.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Vasopressin V1 receptor 2 Target ID: CHEMBL2111456 Sources: http://www.selleckchem.com/products/mozavaptan.html	Antagonist 2849		1.2 µM [IC50]
Vasopressin V2 receptor 16 Target ID: CHEMBL1790 Sources: http://adisinsight.springer.com/drugs/800001739	Antagonist 2849		14.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hyponatremia 4 Sources: http://adisinsight.springer.com/drugs/800001739	Primary		Approved 8583	PHYSULINE Approved Use PHYSULINE is used for the treatment of hyponatremia due to excessive fluid retention when restriction of fluid intake is ineffective. Launch Date 2006

C_max

Value	Dose	Analyte	Population
2.826 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_A102_1.pdf#page=24 \| https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_K115_1.pdf#page=33	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	MOZAVAPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
5.491 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_A102_1.pdf#page=24 \| https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_K115_1.pdf#page=33	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	MOZAVAPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
10.079 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_A102_1.pdf#page=24 \| https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_K115_1.pdf#page=33	90 mg single, oral dose: 90 mg route of administration: Oral experiment type: SINGLE co-administered:	MOZAVAPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4.459 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_A102_1.pdf#page=24 \| https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_K115_1.pdf#page=44	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	MOZAVAPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
4.36 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_A102_1.pdf#page=24 \| https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_K115_1.pdf#page=44	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: Oral experiment type: MULTIPLE co-administered:	MOZAVAPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
3.747 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_A102_1.pdf#page=26 \| https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_K115_1.pdf#page=15	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	MOZAVAPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3.306 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_A102_1.pdf#page=26 \| https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_K115_1.pdf#page=15	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	MOZAVAPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED

AUC

Value	Dose	Analyte	Population
5.84 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_A102_1.pdf#page=24 \| https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_K115_1.pdf#page=33	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	MOZAVAPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
10.89 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_A102_1.pdf#page=24 \| https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_K115_1.pdf#page=33	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	MOZAVAPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
23.54 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_A102_1.pdf#page=24 \| https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_K115_1.pdf#page=33	90 mg single, oral dose: 90 mg route of administration: Oral experiment type: SINGLE co-administered:	MOZAVAPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
8.87 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_A102_1.pdf#page=24 \| https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_K115_1.pdf#page=44	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	MOZAVAPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
10.89 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_A102_1.pdf#page=24 \| https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_K115_1.pdf#page=44	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: Oral experiment type: MULTIPLE co-administered:	MOZAVAPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
7.05 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_A102_1.pdf#page=26 \| https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_K115_1.pdf#page=15	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	MOZAVAPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
9.13 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_A102_1.pdf#page=26 \| https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_K115_1.pdf#page=15	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	MOZAVAPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED

T_1/2

Value	Dose	Analyte	Population
1.75 h OTHER GOV'T https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_A102_1.pdf#page=24 \| https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_K115_1.pdf#page=33	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	MOZAVAPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2.23 h OTHER GOV'T https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_A102_1.pdf#page=24 \| https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_K115_1.pdf#page=33	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	MOZAVAPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2.38 h OTHER GOV'T https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_A102_1.pdf#page=24 \| https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_K115_1.pdf#page=33	90 mg single, oral dose: 90 mg route of administration: Oral experiment type: SINGLE co-administered:	MOZAVAPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2.06 h OTHER GOV'T https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_A102_1.pdf#page=24 \| https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_K115_1.pdf#page=44	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	MOZAVAPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
2.51 h OTHER GOV'T https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_A102_1.pdf#page=24 \| https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_K115_1.pdf#page=44	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: Oral experiment type: MULTIPLE co-administered:	MOZAVAPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED

F_unbound

Value	Dose	Co-administered	Analyte	Population
1.8% OTHER GOV'T https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_A102_1.pdf#page=23			MOZAVAPTAN plasma	Homo sapiens

Doses

Dose	Population	Adverse events
30 mg 1 times / day steady-state, oral Recommended Dose: 30 mg, 1 times / day Route: oral Route: steady-state Dose: 30 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/23761568/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/23761568/	Other AEs: Metastasis... Other AEs: Metastasis (1 pt) Sources: https://pubmed.ncbi.nlm.nih.gov/23761568/
30 mg 1 times / day steady-state, oral Studied dose Dose: 30 mg, 1 times / day Route: oral Route: steady-state Dose: 30 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21087977/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/21087977/	Other AEs: dry mouth, increased blood potassium... Other AEs: dry mouth (5 patients) increased blood potassium (2 patients) malaise (1 pt) increased AST (1 pt) increased ALT (1 pt) decreased blood calcium (1 pt) increased blood lactate dehydrogenase (1 pt) increased blood urea (1 pt) decreased appetite (1 pt) nocturia (1 pt) anorexia (1 pt) Sources: https://pubmed.ncbi.nlm.nih.gov/21087977/

AEs

AE	Significance	Dose	Population
Metastasis	1 pt	30 mg 1 times / day steady-state, oral Recommended Dose: 30 mg, 1 times / day Route: oral Route: steady-state Dose: 30 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/23761568/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/23761568/
anorexia	1 pt	30 mg 1 times / day steady-state, oral Studied dose Dose: 30 mg, 1 times / day Route: oral Route: steady-state Dose: 30 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21087977/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/21087977/
decreased appetite	1 pt	30 mg 1 times / day steady-state, oral Studied dose Dose: 30 mg, 1 times / day Route: oral Route: steady-state Dose: 30 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21087977/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/21087977/
decreased blood calcium	1 pt	30 mg 1 times / day steady-state, oral Studied dose Dose: 30 mg, 1 times / day Route: oral Route: steady-state Dose: 30 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21087977/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/21087977/
increased ALT	1 pt	30 mg 1 times / day steady-state, oral Studied dose Dose: 30 mg, 1 times / day Route: oral Route: steady-state Dose: 30 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21087977/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/21087977/
increased AST	1 pt	30 mg 1 times / day steady-state, oral Studied dose Dose: 30 mg, 1 times / day Route: oral Route: steady-state Dose: 30 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21087977/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/21087977/
increased blood lactate dehydrogenase	1 pt	30 mg 1 times / day steady-state, oral Studied dose Dose: 30 mg, 1 times / day Route: oral Route: steady-state Dose: 30 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21087977/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/21087977/
increased blood urea	1 pt	30 mg 1 times / day steady-state, oral Studied dose Dose: 30 mg, 1 times / day Route: oral Route: steady-state Dose: 30 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21087977/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/21087977/
malaise	1 pt	30 mg 1 times / day steady-state, oral Studied dose Dose: 30 mg, 1 times / day Route: oral Route: steady-state Dose: 30 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21087977/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/21087977/
nocturia	1 pt	30 mg 1 times / day steady-state, oral Studied dose Dose: 30 mg, 1 times / day Route: oral Route: steady-state Dose: 30 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21087977/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/21087977/
increased blood potassium	2 patients	30 mg 1 times / day steady-state, oral Studied dose Dose: 30 mg, 1 times / day Route: oral Route: steady-state Dose: 30 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21087977/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/21087977/
dry mouth	5 patients	30 mg 1 times / day steady-state, oral Studied dose Dose: 30 mg, 1 times / day Route: oral Route: steady-state Dose: 30 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21087977/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/21087977/

PubMed

Title	Date	PubMed
[Vasopressin receptor antagonists: the vaptans].	2010-05	21130961
Inhibitory effect of vasopressin receptor antagonist OPC-31260 on experimental brain oedema induced by global cerebral ischaemia.	2008-03	18288441
Prevention of hypoxic brain oedema by the administration of vasopressin receptor antagonist OPC-31260.	2008	18655905
Gateways to clinical trials.	2003-06	12851663
Ameliorative effect of NC-1900, a new AVP4-9 analog, through vasopressin V1A receptor on scopolamine-induced impairments of spatial memory in the eight-arm radial maze.	2003-03	12646291
Vasopressin V(1) receptor-mediated activation of central sympatho-adrenomedullary outflow in rats.	2002-12-13	12460640
Binding properties of a selective tritiated vasopressin V2 receptor antagonist, [H]-SR 121463.	2000-10	11012895
Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells.	1998-12	9884074
OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.	1998-12	9864265
Identification of residues responsible for the selective binding of peptide antagonists and agonists in the V2 vasopressin receptor.	1998-11-06	9792651
The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways.	1997-10	9322919
Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist.	1992-04	1387020

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dose is one tablet (30 mg) once daily after a meal.

Route of Administration: Oral

In Vitro Use Guide

Mozavaptan caused a concentration-dependent displacement of the selective AVP V2 receptor antagonist radioligand, [3H]desGly-NH2(9)[d(CH2)5, D-Ile2,Ile4]AVP from V2 receptors in rat kidney medulla membranes. The concentration of Mozavaptan that displaced 50% of specific AVP binding (IC50) was 20 +/- 2 nmol/l for renal V2 receptors.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:23:25 GMT 2025` Edited by `admin` on `Mon Mar 31 18:23:25 GMT 2025`
Record UNII	17OJ42922Y
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MOZAVAPTANE

Preferred Name

English

MOZAVAPTAN

Official Name

English

mozavaptan [INN]

Common Name

English

N-(4-(((5RS)-5-(DIMETHYLAMINO)-2,3,4,5-TETRAHYDRO-1H-1-BENZAZEPIN-1-YL)CARBONYL)PHENYL)-2-METHYLBENZAMIDE

Systematic Name

English

Mozavaptan [WHO-DD]

Common Name

English

MOZAVAPTAN [MI]

Common Name

English

MOZAVAPTAN [MART.]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C2180